Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

(NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private equity firms Carlyle ...

Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital ...

That’s what Carlyle and SK Capital are paying for the 15-year-old Massachusetts biotech in a deal that was announced on Friday. There is a catch. If the private equity firms can boost sales of ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

Adi Chugh’s TYKO Capital provided the debt for the partner’s 83-unit condominium project at 401 East 51st Street.

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million. Bluebird on ...

With the backing of Carlyle and SK Capital, we will bring the capital and commercial capabilities needed to accelerate and expand patient access to bluebird’s life-changing gene therapies.” ...

Carlyle and SK Capital will provide bluebird primary capital to scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral ...